PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE

A research group from CIBER has developed a mitochondrial antioxidant for its use in the treatment of Charcot-Marie-Tooth disease

The Need
Charcot Marie Tooth (CMT) disease is a neuropathy for which there are currently no effective treatments.

CMT is a rare disease, being the most common inherited condition of the peripheral nervous system, with an estimated prevalence of 10-28/100,000 inhabitants.

The Solution
The present technology provides a pharmaceutical composition comprising MitoQ for the treatment of CMT symptoms, specially if the cause of the disease being genetic alterations in GDAP1 and/or MFN2.

Innovative Aspects
The composition, MitoQ, has no toxic effects. In addition, it is currently marketed as a dietary supplement for humans.

The main advantage of treatment with the pharmaceutical composition is the reduction of symptoms related to motor deficiencies of the lower extremities.

In addition, MitoQ has been shown to prevent the development of the associated phenotype and motor deficits associated with CMT disease in Gdap1-/- mice.

Stage of Development:
Preclinical stage.

Intellectual Property:
- Priority Spanish patent application filed
- Suitable for international extension (PCT application)

Aims
Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details
Centro de Investigación Biomédica en Red (CIBER)
jlque@ciberer.es
otc@ciberisciii.es
https://www.ciberisciii.es/en